EISAI R & D MANAGEMENT CO., LTD. Patent applications |
Patent application number | Title | Published |
20140349879 | METHOD FOR DETECTING NUCLEOTIDE MUTATION, AND DETECTION KIT - Provided are a detection method and detection kit for detecting a nucleotide mutation simply, with highly sensitivity and high specificity, which allow a plurality of samples to be simultaneously detected in a single measurement. The detection method includes the steps of: amplifying a nucleic acid to be tested to obtain a DNA amplification product; subjecting the DNA amplification product, a first nucleic acid probe having a region complementary to a first region of the DNA amplification product, a second nucleic acid probe having a region complementary to a second region of the DNA amplification product, and a plurality of kinds of signal amplification probes to be used in a PALSAR method to a reaction to form a complex for detection including a probe polymer; and detecting the probe polymer bound in the complex for detection to detect the presence or absence of a mutation in a nucleotide mutation site of the DNA amplification product, the first region of the DNA amplification product including the nucleotide mutation site, the nucleotide mutation site being located at a portion other than both end portions of the first region, the second nucleic acid probe having a base sequence identical to part or all of the base sequence of one of the signal amplification probes. | 11-27-2014 |
20110143382 | IgA Nephropathy Testing Method And Test Kit - There is provided a renal disease testing method comprising a complex detection step of detecting a complex of an antigen derived from human renal mesangial cells and human IgA in a sample derived from urine collected from a subject. It is preferred that the renal disease testing method of the invention further comprises a determination step of assessing the whether the renal disease is IgA nephropathy based on the ratio of the amount of the complex detected in the complex detection step to the amount of urinary proteins in the sample. The renal disease testing method of the invention has good detection sensitivity and specificity, and can conveniently and safely assess the existence of a renal disease (preferably, IgA nephropathy). | 06-16-2011 |
20110060151 | REAGENTS AND METHODS FOR THE BETA-KETO AMIDE SYNTHESIS OF A SYNTHETIC PRECURSOR TO IMMUNOLOGICAL ADJUVANT E6020 - This invention relates to the synthesis for a precursor of E6020, compound 26, via a β-keto amide alcohol intermediate, compound 22. The synthesis reacts compound 22 with compound 25 and the resultant intermediate is oxidized to produce compound 26, the precursor to E6020. Compounds 22 and 25, and their crystalline forms, represent separate embodiments of the invention. The invention also relates to compounds of formulas (3) and (4) and processes for their preparation. | 03-10-2011 |
20100303771 | GABA NEURON PROGENITOR CELL MARKER 65B13 - The present inventors identified a selective marker 65B13 for GABA neuron progenitor cells of the spinal dorsal horn and cerebellum, and successfully isolated GABA neuron progenitor cells using antibodies that bind to a protein encoded by the gene. 65B13 was demonstrated to be useful as a marker to isolate GABA-producing neuron progenitor cells in the spinal dorsal horn and cerebellum. GABA neuron progenitor cells can be efficiently identified or isolated by using the identified marker as an indicator. | 12-02-2010 |
20100222354 | AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain - The invention provides methods for treating and/or preventing neuropathic pain by administering to patients therapeutically effective amounts of AMPA receptor antagonists and aldose reductase inhibitors. The neuropathic pain may be diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and aldose reductase inhibitors. The AMPA receptor antagonists may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The aldose reductase inhibitor may be, for example, ranirestat. | 09-02-2010 |
20100197951 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT - The present invention provides methods for preparing TLR-4 receptor agonist E6020: | 08-05-2010 |
20100190184 | SCREENING METHOD UTILIZING NOVEL SUBSTRATE C-RET FOR GAMMA-SECRETASE - The present invention provides a method of screening for compounds which affect the processing of c-Ret by γ-secretase. The method involves contacting a first biological composition containing γ-secretase or a biologically active fragment thereof with a second biological composition containing c-Ret in the presence and absence of a candidate compound; measuring the cleavage of the c-Ret in the presence and absence of the candidate compound; selecting those candidate compounds which affect the cleavage of the c-Ret by γ-secretase; and identifying the candidate compounds selected in the previous step as compounds which affect the processing of c-Ret by γ-secretase. | 07-29-2010 |
20100068274 | PROCESS FOR PRODUCTION OF TABLET - An object of the present invention is to provide a dry coating method which can coat a tablet in a simple manner and with high efficiency, and therefore can produce a tablet having good appearance and hardly causing breaking/cracking. The present invention provides a process for producing a tablet coated with a coating agent comprising a meltable substance, comprising the steps of: heating a plain tablet to a temperature equal to or higher than a melting point of the meltable substance; and contacting the plain tablet with the coating agent to coat the plain tablet. | 03-18-2010 |
20100048503 | COMPOSITION FOR TREATMENT OF PANCREATIC CANCER - Disclosed are a pharmaceutical composition having excellent antitumor activity, and a method for treating a cancer. Specifically, excellent antitumor activity is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogous compound thereof, a pharmacologically acceptable salt thereof or a solvate thereof is used in combination with gemcitabine or erlotinib, a pharmacologically acceptable salt thereof or a solvate of any of them. | 02-25-2010 |
20100035878 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION - The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation. | 02-11-2010 |
20100016362 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING DONEPEZIL, PROCESS OF PRODUCING SAME AND METHOD FOR STABILIZATION - An object of the present invention is to provide a novel pharmaceutical composition containing donepezil, which is already used as a remedy for the treatment of dementia (cognitive impairment), in order to increase options for administration methods and improve patient compliance. The present invention provides a pharmaceutical composition containing donepezil or a pharmaceutically acceptable salt thereof and a naturally-occurring polymer, the pharmaceutical composition further containing at least one of edetate, sulfite, dibutylhydroxytoluene and butylhydroxyanisole. | 01-21-2010 |
20100004433 | NOVEL COLLAGEN-LIKE PROTEIN CLAC, PRECURSOR THEREOF AND GENES ENCODING THE SAME - A novel human collagen-like protein CLAC occurring in brain amyloid and its precursor CLAC-P; genes encoding the same; cDNA of mouse CLAC-P and its deduced amino acid sequence; antibodies specific to these proteins; and methods of diagnosing treating and preventing Alzheimer's disease by using the same. | 01-07-2010 |
20090280530 | NOVEL COLLAGEN-LIKE PROTEIN CLAC, PRECURSOR THEREOF AND GENES ENCODING THE SAME - A novel human collagen-like protein CLAC occurring in brain amyloid and its precursor CLAC-P; genes encoding the same; cDNA of mouse CLAC-P and its deduced amino acid sequence; antibodies specific to these proteins; and methods of diagnosing treating and preventing Alzheimer's disease by using the same. | 11-12-2009 |
20090275049 | EphA4 POLYPEPTIDE HAVING A NOVEL ACTIVITY AND USE THEREOF - The present invention provides a polynucleotide which consists of a partial sequence of a polynucleotide encoding the amino acid sequence as shown in SEQ ID NO: 2, wherein the former polynucleotide encodes a polypeptide consisting of a partial amino acid sequence of SEQ ID NO: 2 whose N-terminus starts between positions 564 and 621 of SEQ ID NO: 2. | 11-05-2009 |
20090264464 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER - The present invention relates to a therapeutic agent represented by the General formula (I), or a pharmacologically acceptable salt thereof, or a solvate of the compound or the salt thereof: | 10-22-2009 |
20090259049 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS - A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. | 10-15-2009 |
20090247576 | ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA - The object of the invention is to provide a pharmaceutical composition and a therapeutic method which can exert their effects with higher efficiency on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR3, a cell that has a t(4;14) translocation and a cell expressing mutant FGFR3. The compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof can exert their effects with higher efficiency on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR3, a cell that has a t(4;14) translocation and a cell expressing mutant FGFR3. | 10-01-2009 |
20090239216 | Novel Tannase Gene And Protein Thereof - A polynucleotide encoding a protein as defined in the following (a), (b) or (c):
| 09-24-2009 |
20090209580 | ANTITUMOR AGENT FOR THYROID CANCER - The objective of the present invention is to provide a pharmaceutical composition and a therapeutic method that are specifically effective against at least one disease selected from multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract. | 08-20-2009 |
20090208579 | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same - A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a dissolution rate of the basic drug or the salt thereof in an acidic test solution to a dissolution rate of the basic drug or the salt thereof in a neutral test solution (dissolution rate in the acidic test solution/dissolution rate in the neutral test solution) decreases with dissolution time at the late stage of dissolution, as compared to the early stage of dissolution. According to the present invention, the matrix type sustained-release preparation contains a basic drug or a salt thereof and at least one enteric polymer, in which solubility of the basic drug or the salt thereof in a 0.1 N hydrochloric acid solution and a neutral aqueous solution, pH 6.0 is higher than in a basic aqueous solution, pH 8.0. | 08-20-2009 |
20090203693 | THERAPEUTIC AGENT FOR LIVER FIBROSIS - The present invention provides a therapeutic agent for hepatic fibrosis and a method for treatment of hepatic fibrosis. 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogue thereof can prevent the fibrillation in the liver, and therefore can be used as a therapeutic agent for hepatic fibrosis or in the method for treatment of hepatic fibrosis. | 08-13-2009 |
20090203046 | METHODS FOR IDENTIFYING PURKINJE CELLS USING THE CORL2 GENE AS A TARGET - Total RNAs were prepared from the ventral and dorsal regions of embryonic day 12.5 mouse mesencephalon, and a cDNA fragment was obtained by the subtraction method (N-RDA). The full-length cDNA was cloned and the nucleotide sequence was determined. The gene was named Corl2. The result of homology search showed that about 850 residues of Corl2 exhibited homology to the XM_355050 sequence deposited in GenBank; however, the remaining ˜150 residues showed no homology. Thus, Corl2 was demonstrated to be a novel gene. The Corl2 expression in various mouse organs was analyzed by RT-PCR, and the result showed that Corl2 expression was specific to brain. The result of immunostaining day 12.5 embryos and postnatal day 12 brains demonstrated that Corl2 is useful as a Purkinje cell marker at any differentiation stages. | 08-13-2009 |
20090191580 | METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE - The present invention relates to a method of screening for compounds which affect the processing of c-Met by γ-secretase, comprising the following steps:
| 07-30-2009 |
20090148960 | Method for analysis of compound-binding ability of protein - The present invention provides a method for analyzing a binding ability of protein to a compound, comprising the steps of (a) fractionating a first group of isotope-labeled proteins into plural fractions using a carrier having the compound immobilized thereon; (b) fractionating a second group of proteins into one or plural fractions using a carrier having the compound immobilized thereon; (c) adding a certain amount of the one fraction obtained in step (b), or a certain amount of a mixture of all the fractions or a mixture of plural contiguous fractions among the fractions obtained in step (b), to each of the fractions obtained in step (a); (d) analyzing the fractions obtained in step (c) with mass spectrometry; and (e) based on the mass spectrometry information, obtaining, regarding each fraction, an intensity ratio between a peak derived from a protein in the fraction obtained in step (a) and a peak derived from a protein in the fraction obtained in step (b), and comparing degrees of the binding ability of the plural kinds of proteins to the compound. | 06-11-2009 |
20090142788 | SCREENING METHOD USING NEW SUBSTRATE EPHA4 OF GAMMA-SECRETASE - The present invention provides a method of screening for compounds which affect the processing of EphA4 by γ-secretase, comprising the following steps:
| 06-04-2009 |
20090110727 | Extended release compositions of proton pump inhibitors - The invention provides extended release compositions comprising at least one proton pump inhibitor. The invention also provides methods for treating gastrointestinal disorders by administering the compositions of the invention to patients in need of gastrointestinal therapy. | 04-30-2009 |
20090069591 | Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof - The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof. | 03-12-2009 |
20090053236 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR - The object of the present invention is to find a pharmaceutical composition and a method for treating cancer that show an excellent antitumor effect. Combinational use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogues thereof can result in an excellent antitumor effect when combined with a substance having a c-kit kinase-inhibiting activity. | 02-26-2009 |
20090047365 | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent - The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and/or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic. | 02-19-2009 |
20090047278 | Novel Combinational Use of Sulfonamide Compound - The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer, comprising a sulfonamide compound in combination with a substance having an EGF inhibitory activity. | 02-19-2009 |
20090030017 | THERAPEUTIC AGENT FOR DYSKINESIA - The present invention relates to a therapeutic agent for dyskinesia excluding tremor, comprising 1,2-dihydropyridine compound, a salt thereof, or a solvate thereof, which shows AMPA receptor antagonism and is highly useful as a pharmaceutical drug. | 01-29-2009 |
20080286282 | Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor - The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab. | 11-20-2008 |
20080221802 | Method of Proteome Analysis for Phosphorylated Protein - A method for detecting plural types of phosphorylated proteins in a sample, wherein a database consisting of data regarding plural types of proteins in the sample is used; and a method for purifying phosphorylated proteins using an immobilized metal carrier or a titania carrier, wherein a solution containing acetonitrile in a range of 40% (v/v) or greater but 60% (v/v) or less is used. | 09-11-2008 |
20080213368 | Method for Stabilizing Anti-Dementia Drug - The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug. | 09-04-2008 |